Background: Circulating-free DNA (cfDNA) is under investigation as a liquid biopsy of cancer for early detection, monitoring disease progression and therapeutic response. This systematic review of the primary cfDNA literature aims to identify and evaluate factors that influence recovery of cfDNA, and to outline evidence-based recommendations for standardization of methods. Methods: A search of the Ovid and Cochrane databases was undertaken in May 2018 to obtain relevant literature on cfDNA isolation and quantification.
Introduction
In healthy individuals, circulating-free DNA (cfDNA) originates from apoptosis of nucleated cells and is found at low levels in blood (Stroun et al., 2001 ) but can increase following exercise (Fatouros et al., 2010) . In malignancy, the tumor derived fraction of total cfDNA, termed circulating tumor DNA (ctDNA), can derive from tumor cells by a combination of apoptosis, necrosis and active secretion (Stroun et al. 2001; Jahr et al., 2001) , and from disseminated tumor cells in micrometastatic deposits (Shaw et al., 2012; Gonz alez-Masi a et al., 2013) . Numerous studies have demonstrated the potential of genetic and epigenetic alterations in ctDNA as tumor-specific biomarkers to facilitate detection of resistance and relapse, and for prediction of response to treatment (Alix-Panabi eres and Pantel, 2016; Heitzer et al., 2015; Diaz et al., 2016) .
The number of cfDNA-related publications has risen rapidly since the mid-1990s ( Fig. 1 and Supplemental Table S1 ). However, the community is yet to agree on a consensus for the isolation and analysis of cfDNA, thus limiting comparison between studies. This issue was highlighted at the consensus meeting on cfDNA, hosted by the Experimental Cancer Medicine Centre (ECMC) Network and the National Cancer Research Institute Biomarkers and Imaging Clinical Studies Group (UK). It was agreed that a systematic review would be of use to the cfDNA community to identify and evaluate the methodological factors that influence quality and yield of cfDNA (ECMC, 2014) . In support of this, there is wide variation in the methods used to isolate plasma from whole blood and to extract cfDNA (Fig. 2) .
We randomly sampled 50 primary research articles published in 2015 relating to cfDNA in cancer and found deficiencies in reporting of methodology. Sixteen articles provided no information regarding plasma/serum isolation and a further 19 mentioned centrifugation but did not state the speed or number of centrifugation steps. Lastly, 18 articles provided no information on cfDNA quantification prior to downstream analysis (Supplemental Table S2 ). Therefore, we carried out a systematic review of the cancer cfDNA literature with the aim of providing a series of methodological recommendations to promote optimal and reproducible processing and analysis of cfDNA. After scoping the literature, we determined there was sufficient information to examine the following factors: (1) choice of specimen type (plasma or serum); (2) time-to-processing of whole blood and choice of blood specimen tube; (3) centrifugation speed, number of spins and centrifugation time of whole blood; (4) cfDNA isolation method; and (5) cfDNA quantification method.
The search was updated in May 2018 to ensure inclusion of recent publications.
Materials and methods
This systematic review was guided by the criteria of the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) (Supplemental Table S3 ) (Moher et al., 2010) . OR ptDNA OR serum DNA OR serum cell-free) AND (cancer OR neoplas* OR tumor). Publications relating to cell-free DNA in non-blood analytes (e.g. urine and ascites) and cell culture media were not included. A yearly breakdown of publication types is presented in Supplemental Table S1 . 
Literature search strategy
An initial scoping search in Ovid (Embase and Medline) was carried out to assess for appropriateness, and relevant publications were identified from which keywords were obtained. A comprehensive publication search was conducted in the PubMed, Ovid (Embase and Medline) and Cochrane library databases prior to July 28, 2017 (updated to May 5, 2018 without limits for language, publication type or publication date. Keywords were chosen to reflect the concepts of 'circulating-free DNA', 'cancer' and 'methodology', with provision for alternative spellings, synonyms and abbreviations for circulating-free DNA. Keywords were combined using Boolean operators and translated into database-specific syntax, and were searched in title and abstract only. The final search strategy was as follows: ((ccfDNA OR cfDNA OR cfNA OR ctDNA OR cell-free DNA OR cell free DNA OR cell-free serum DNA OR circulating DNA OR circulating free DNA OR circulating-free DNA OR circulating nucleic acids OR circulating tumo?r DNA OR free DNA OR free tumo?r DNA OR plasma DNA OR plasma tumo?r DNA OR ptDNA OR serum DNA OR serum cell-free) AND (cancer OR neoplas* OR tumo?r) AND (process* OR isolat* OR centrifug* OR spin* OR extract* OR quanti* OR sensitiv* OR specific* OR measur*)). Question marks and asterisks represent optional wildcards and truncations, respectively. As an example, the search strategy for Ovid (Embase and Medline) is shown in Table 1 . All returned studies were reviewed by title and abstract by two authors. Additional studies were identified through a manual search of bibliographies in included studies and relevant narrative reviews. Authors of the following publications were contacted by email for further information : Chiminqgi et al., 2007; Holdenrieder et al., 2005; Morgan et al., 2012; Swinkels et al., 2003; and Taback et al., 2004 . Conference abstracts were excluded due to insufficient detail for valid assessment.
Selection criteria
Studies investigating the effect of methodological factors on quality and/or yield of cfDNA proceeded to full-text review. The criteria for inclusion were as follows: (1) provided a direct comparison between two or more protocols in processing/analysis of circulating-free DNA; (2) n ! 5 for any comparative study; and (3) absolute values stated (or available through author contact) for quantitative data. The criteria for exclusion were as follows: (1) n < 5 for any comparative study; (2) only pregnant female subjects; (3) qualitative data or insufficient data available (despite further information provided by author contact) for valid analysis; (4) specific research questions not addressed; (5) unsuitable publication types, such as commentaries, editorials and review articles without data; and (6) duplicate publication. All included studies (n ¼ 36) and 320 randomly selected publications, approximately 10% of the total, were verified for eligibility by a second independent reviewer (LJM). Included studies were also reviewed to check for additional references not generated by the data mining process.
Data extraction and analysis
The following data were independently extracted into an electronic table by two reviewers: first author, year of publication, number of subjects in each group, health status of subjects, gender of subjects (if stated), cfDNA isolation method, cfDNA quantification method, technical details of protocol and mean (with standard deviation and/or range if stated) of any measurements. Where data were presented graphically but not specified numerically, individual data points were estimated by two observers by interpolating graphs. A quantitative analysis was not deemed possible, due to significant heterogeneity in methodological approaches between studies.
Therefore, included data was tabulated and a textual qualitative synthesis approach was taken. 3. Results
Literature search and study characteristics
The literature search and inclusion/exclusion process is shown in Fig. 3 . A total of 5,888 articles were identified through database searching and 4,172 articles remained after duplicated articles were removed. All articles were screened with title and abstract against the inclusion and exclusion criteria, and 48 articles proceeded to fulltext review. The review process identified a further 4 articles. Of the 52 articles that were reviewed by full-text, 15 were excluded for one or more of the following reasons: (i) insufficient cohort size (n < 5) for a comparative study (n ¼ 5); (ii) only pregnant female subjects (n ¼ 1); (iii) insufficient quantitative data (n ¼ 4); (iv) specific research questions not addressed (n ¼ 4); and (v) duplicated data from another publication (n ¼ 1). Studies with only pregnant female subjects were not included, as the biological characteristics of fetal cfDNA may not be comparable to those for tumor-derived cfDNA. Due to the broad search strategy adopted, a large number of publications were retrieved.
A total of 37 articles met all inclusion criteria and no exclusion criteria, and were included in the narrative synthesis (Table 2 ). Studies were published between healthy subjects only, 17 recruited patients with cancer only, and 6 recruited both.
One study recruited patients with suspected cancer and one study combined patients with different health statuses into a single cohort for analysis. Cohort size ranged between 5 and 156 subjects.
Ten studies investigated cfDNA levels in matched plasma and serum, 19 studies investigated the effect of time delay post-venepuncture on cfDNA levels in plasma using different collection tubes, 6 studies investigated the effect of centrifugation speed and time on cfDNA levels in plasma, 10 studies compared efficiency of cfDNA extraction between different commercially available kits, and 8 studies compared methods of cfDNA quantification. Several different methods were used to quantify cfDNA. Polymerase chain reaction (PCR) was the most commonly used method, with 27 studies using quantitative real-time PCR (qPCR) and 7 studies using digital PCR (dPCR). Ten studies used a fluorescent DNA-binding dye (fluorometry), and one study used ultraviolet spectrophotometry. Eight studies utilized two or more quantification methods. The cfDNA concentration was expressed as either ng/mL or haploid genome equivalents (copies)/mL. Two studies reported total amounts per plasma/serum sample, one study used cell equivalents/mL and one study used copies/mL. To permit a direct comparison between studies in this review, haploid genome equivalents (copies) were multiplied by 3.3 Â 10 À3 to give ng.
Lastly two qPCR-based studies reported cycle threshold (C T ) values only which
could not be interpolated to give the cfDNA concentration.
Choice of specimen type (plasma or serum)
Ten studies investigated yield of cfDNA from matched plasma and serum samples.
Total cfDNA levels were between 1.63 and 11.09-fold higher in serum than in plasma of healthy controls and patients with cancer (Table 3) . Two studies that met the inclusion criteria also assessed integrity of cfDNA in plasma and serum Holdenrieder et al., 2008) . Using a ratio of 201 bp/105 bp amplicons, cfDNA isolated from serum was found to have significantly higher integrity than that from plasma (50% vs 33%, respectively). This difference in integrity between specimens was greater with a 356 bp/105 bp ratio, at 26% vs 12% for serum and plasma, respectively, thus supporting the presence of high molecular weight DNA from hematopoietic cells in serum . Although KRAS allelic frequencies were much lower than expected in serum samples compared to plasma (Kloten et al., 2017) , serum was still a useful source for recovery of ctDNA, as plasma and serum were comparable in terms of sensitivity (31% and 25%, respectively) and specificity (97% and 100%, respectively) (Morgan et al., 2012) .
Time-to-centrifugation of blood and blood specimen tube
The effect of time delay between venepuncture and centrifugation of blood on cfDNA levels has been reported by several groups, with the general observation that cfDNA levels increase over time prior to centrifugation of EDTA-stabilized blood (Page et al., 2011) . To overcome the need for immediate blood processing, specialized blood collection tubes are available that contain a preservative agent to prevent lysis of peripheral leukocytes and permit storage of whole blood at room temperature for several days prior to centrifugation; these include the CellFree DNA BCT Ò (Streck) and PAXgene Ò Blood DNA Tube (Qiagen). Nineteen studies investigated the effect of time-to-centrifugation of blood on levels of cfDNA over time points ranging up to 14 days ( and PAXgene Ò Blood DNA Tube), and one study compared two specialized tubes. Table 4 summarizes the included studies and shows the stability of blood, which was defined as the longest time post-venepuncture at which cfDNA levels remained stable relative to at baseline levels (i.e. immediate centrifugation of blood), as determined by the Student's t-test on paired plasma samples.
Of the studies that investigated EDTA tubes, 10 studies included a baseline of 0 hours (i.e. immediate centrifugation) and the minimum stability was 6 hours in these studies. Two studies did not assess stability beyond 6 hours and in both studies cfDNA was stable for this time. Concerning longer times to processing, 6 of 9 studies that included a 24 hour time point reported stability for this duration.
Ten studies used the Cell-Free DNA BCT In the 2 studies that used CellSave tubes, cfDNA was stable up to the last time point (48 hours and 4 days). One study used the PAXgene Ò Blood DNA Tube and assessed cfDNA levels after 24 hours and 7 days. Here cfDNA levels were significantly elevated after 7 days.
Centrifugation protocol: speed, time, temperature and number of spins
Six studies investigated the effect of centrifugation speed (range, 400ge16,000g) on cfDNA recovery from EDTA plasma, and 5 of these studies also investigated the addition of a second centrifugation step (Table 5) . A second centrifugation step had no significant effect on DNA yield apart from in one study where this was associated with a significant reduction, suggesting that differences may be due to removal of plasma without disturbing the buffy layer after the first spin. Lui et al. (2002) observed no significant differences in DNA yield with single centrifugations of 10 minutes at 400g, 800g, 1,500g, 3,000g and 16,000g. Similarly, Page et al. (2013) reported no significant difference in DNA yields at 1,000g, 2,000g and 10,000g 11,000* for 10 minutes. However, Swinkels et al. (2003) reported that after an initial centrifugation at 800g for 10 minutes, a second centrifugation step at 16,000g for 10 minutes significantly reduced DNA yield. Interestingly, Sherwood et al. (2016) found that double centrifugation at 2,000g for 10 mins did not decrease DNA yield relative to single centrifugation of blood processed 2 hours post-collection, but the second step significantly reduced DNA yield in blood processed 72 hours post-collection.
This suggests that contaminating nuclear DNA was present at 72 hours due to lysis of white blood cells that was not efficiently pelleted by a single centrifugation step.
Lastly, van Ginkel et al. (2017) also incorporated a freeze thaw step between the first and second centrifugation steps, but this did not affect recovery.
Four studies Garcia et al., 2017; Jung et al., 2003; Kang et al., 2016) investigated the effects of storage temperature of unprocessed blood in EDTA tubes and reported no significant influence of temperature on resulting cfDNA levels.
Methods of cfDNA isolation and quantification
Methods of cfDNA isolation reported varied from in-house protocols to the use of commercially available kits. Of these, the QIAamp Ò Circulating Nucleic Acid Kit (Qiagen) was most widely used (Tables 6 and 7) . Page et al. (2013) showed that this kit led to the highest yield of total cfDNA. qPCR was the most widely used method for cfDNA quantification, while fluorometry (e.g. PicoGreen Ò and Qubit
was also widely used as a cost-effective, rapid and simple method. Ramachandran et al. (2013) also compared qPCR with fluorometry and UV spectrophotometry (Table 7) . Total cfDNA levels were significantly correlated in all studies that compared qPCR and fluorometry (PicoGreen Ò or Qubit Ò ) (r ! 0.72; P < 0.05), except for in one study (Mauger et al., 2015) . Ramachandran et al. (2013) reported that cfDNA levels quantified by qPCR were not significantly correlated with UV spectrophotometry (r ¼ 0.23) (not included in Table 7 ) and van Ginkel showed positive correlation between dPCR and fluorometry by Qubit (r ¼ 0.98; P < 0.0001) but not UV spectrophotometry (Nanodrop).
Discussion
We systematically reviewed the cfDNA literature in order to investigate the influence of preanalytical and analytical factors on quality and/or yield of cfDNA for subsequent molecular analysis of ctDNA. Of 4,176 articles retrieved by database and bibliography searching, 37 articles were identified that met all inclusion criteria and were included in the review. Given the heterogeneity observed across the included studies, we took a narrative approach to data synthesis and tabulated the relevant data to examine the following factors: (1) choice of specimen type (plasma or serum); (2) time-to-processing of whole blood and choice of blood specimen tube; (3) centrifugation speed, time, temperature and number of spins of whole blood; (4) cfDNA isolation method; and (5) cfDNA quantification method. Table 8 summarizes the evidence-based methodological recommendations to promote best practice in processing and analysis of cfDNA. Ten of the included studies assessed cfDNA levels in paired plasma and serum samples from healthy subjects and/or patients with cancer. All 10 studies (Table 3) reported a significant increase in cfDNA levels in serum relative to plasma, likely due to lysis of white blood cells in serum during clotting. In support of this, one study also compared DNA integrity, which was higher in serum than plasma, confirming likely release of DNA from white blood cells . Accordingly, use of plasma is preferable for applications where detection of tumorspecific alterations may be masked by extraneous wild-type DNA, and the limit of detection of a specific variant may be compromised.
Immediate processing of blood by centrifugation may not always be possible in the clinical setting; for example, a centrifuge may not be available on-site or blood samples may be taken over a period of time during a clinic. Consistent with the notion of DNA contamination in serum, the included studies reported a general increase in cfDNA levels over time in unprocessed serum and EDTA blood, albeit at a slower rate. There was significant heterogeneity in study design, with studies measuring cfDNA levels at intervals of several hours to several days, and with some studies omitting a baseline time point (i.e. immediate processing).
In this review, the term 'stability' is used to refer to the longest time point postvenepuncture in which cfDNA levels did not significantly change relative to at baseline (i.e. the first time point in each study). Nineteen studies investigated the effect of a delay in blood processing on yield of cfDNA from plasma. Nine studies used ETDA tubes only, 8 studies compared EDTA tubes with one or more specialized cfDNA preservation tubes (Cell-Free DNA BCT Ò , CellSave and PAXgene Ò Blood DNA Tube) and 1 study compared two specialized tubes. All studies using EDTA tubes reported stability of cfDNA for at least 6 hours, and up to 24 hours in several studies Table 8 . Evidence-based methodological recommendations for processing and analysis of cfDNA.
*insufficient data available to comment on other methods (e.g. digital PCR).
Methodological factor Recommendation Justification
Blood specimen type Plasma for analytical techniques that are sensitive to a wild-type DNA background; plasma or serum for all other techniques.
cfDNA levels in serum appear significantly greater than in plasma due to contamination from genomic DNA.
Storage conditions of blood and time to processing
Store EDTA blood at either room temperature or 4 C and process within 6 hours. Specialist tubes should adhere to manufacturers' guidelines.
Storage of blood at room temperature does not influence cfDNA yield relative to storage at room temperature. cfDNA levels increase in EDTA blood processed after 6 hours.
Centrifugation speed and time of blood
Spin blood and then re-spin plasma prior to storage for cfDNA isolation (double spin). Centrifugation speed and temperature (room temperature or 4 C) is not critical.
Plasma can be contaminated with cells from the buffy layer. The second spin helps to minimize the potential for contamination of plasma with cells from the buffy layer.
Method of cfDNA isolation and quantification
Follow manufacturers recommendation for cfDNA isolation. Quantify by qPCR or fluorometry.
Quantification of cfDNA shows good agreement by qPCR, dPCR and fluorometry.* (Board et al., 2008; Kadam et al., 2012; Norton et al., 2013; van Dessel et al., 2017; van Ginkel et al., 2017) . Several studies (Denis et al., 2015; Rothwell et al., 2016; Sherwood et al., 2016; Toro et al., 2015; van Dessel et al., 2017) did not process blood immediately, instead using 1, 2 or 4 hours as the first time point. However, based on data from the 10 studies that processed blood immediately, it was unlikely that cfDNA levels increased in blood over 1, 2 and 4 hours post-venepuncture. Hence, up to 4 hour time points were considered a suitable baseline. Four studies stored paired blood samples at room temperature and 4 C, but did not observe any significant influence of temperature on cfDNA yield. Based on the minimum period of cfDNA stability reported across these studies, it is preferable that EDTA blood is processed ideally within 6 hours of venepuncture and stored either at room temperature or 4 C during this time. While the Cell-Free DNA BCT Ò is reported to stabilize blood for up to 14 days post-venepuncture, only one study in this review included time points that extended to 14 days; and blood was reported to be stable for up to 7 days, but not 14 days. Another study reported stability for up to 10 days and the other studies that assessed the Cell-Free DNA BCT Ò reported stability up to the last time point (ranging from 24 hours to 7 days). Seven days is therefore a sensible maximum time to processing for samples from Cell-Free DNA BCTÒ tubes.
Protocols for isolation of plasma from whole blood must ensure the resultant plasma is completely acellular to prevent contamination with genomic DNA. This review included 6 studies that compared the effect of centrifugation speed (range, 400e16,000g) and the number of centrifugation steps (1e4) on cfDNA yield from plasma. The use of a second centrifugation step is common practice due to possible disturbance of cells in the buffy layer on removal of plasma. This is supported by one study that used a second centrifugation step of 16,000g after a lower 800g first step that reported a significant decrease in cfDNA yield relative to the single step alone (P ¼ 0.01) (Swinkels et al., 2003) . A double-centrifugation protocol is desirable to minimize the potential for contamination of plasma with cells in the buffy layer such that carry over of cells from the first centrifugation will be pelleted in the second centrifugation. However, centrifugation speed and temperature are not critical as these did not influence cfDNA recovery.
Methods of cfDNA isolation vary with different commercially available kits. All require adherence to the protocol to minimize variability in recovery of cfDNA.
There are also a number of validated automated platforms available, which minimise hands-on time and should aid in standardization, although none were tested in the studies evaluated in this review. Among the methods analyzed in these studies, the Qiagen QIAamp Ò CNA Kit and DNA Blood Mini Kit were the most widely used methods. Quantification of cfDNA was predominantly carried out by either qPCR or fluorometry, which showed good agreement. Where qPCR is not available, fluorometry is a quick and cost-effective method of cfDNA quantification, within the limits of the particular assay. An advantage of PCR-based quantification is that it can help to assess the likelihood of successful downstream analysis by NGS, qPCR or digital PCR (dPCR).
Based on this systematic review, we have summarized evidence-based methodological recommendations to promote best practice in processing and analysis of cfDNA (Table   8 ). This review is therefore an important step in enabling research groups to increase comparability between cfDNA analyses, helping to facilitate translation of cfDNA into multi-center clinical trials as a step towards implementation in the clinic. To ensure rapid dissemination of the results and to reach an analytical consensus in the field, the use of uniform units should also be considered for adoption by the scientific community.
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